Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 04:12:58 - browse：284

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Archived: an online chat discussing Ebola, vaccines, and a new epidemic

WSS

Protect nursing home residents from future pandemics

Should insurance cover cosmetic surgery?

Skip the lead apron during X

Bird flu makes raw milk dangerous to consume, mouse study finds

Some medical students still think black patients feel less pain

Ozempic cut risk of death in diabetes patients with chronic kidney disease

knowledge

Wikipedia

leisure time

Heart attack and stroke risk calculators need revising

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Moonlake's readout produced a cash windfall. Risks remain

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

How one medical school became remarkably diverse

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Heart attack and stroke risk calculators need revising

New research sheds light on how often breast cancer is overdiagnosed

Guidelines to prevent youth baseball injuries need more muscle

Drug cartel violence flares in western Mexico after vigilante leader's killing

explore

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

AstraZeneca lung cancer study comes in below expectations

Pharma’s losing bet in New Jersey

Protect nursing home residents from future pandemics

explore

hotspot

hotspot

focus